HFA Icon

SohnX Hong Kong: Gabriel Grego of Quintessential Capital on why he’s short Cassava Sciences

Michelle headshot
Michelle deBoer-Jones
Published on
Sign up for our E-mail List and Get FREE Access to Exclusive Investment E-books and More!

The field of short-sellers has shrunk dramatically since the Department of Justice's probe was revealed earlier this year. However, some stalwart investors remain committed to the cause of unveiling potentially fraudulent companies.

Background On Cassava Sciences, Formerly Known As Pain Therapeutics

At the SohnX Hong Kong Conference, reputable short-seller Gabriel Grego of Quintessential Capital Management unmasked the individuals behind Cassava Sciences, previously known as Pain Therapeutics. He also explained why he sees problems at the company that has caused him to flag it as potentially fraudulent.

Q2 2022 hedge fund letters, conferences and more

Gabriel Grego

Grego began his campaign against Cassava Sciences in November 2021, although he suggested that some investors might...

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Premium Members Get EVEN MORE VALUE

Subscribe to Hedge Fund Alpha

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe and get an extra 20% off annual with code LETTERS
Michelle headshot

Michelle deBoer-Jones is editor-in-chief of Hedge Fund Alpha. She also writes comparative analyses of stocks for TipRanks and runs Providence Writing Services. Previously, she was a television news producer for eight years, producing the morning news programs for NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spending a short time at the CBS affiliate in Huntsville.